Dexlansoprazole Absorption and Marginal Ulceration After Gastric Bypass

Spital Limmattal Schlieren

Status and phase: Withdrawn; Phase 4

Conditions: Bariatric Surgery

Treatments: Diagnostic Test: dexlansoprazole serum concentration; Diagnostic Test: upper endoscopy

Study type: Interventional

Funder types: Other

Identifiers

NCT04423588

2019-02326

Details and patient eligibility

About

In Switzerland, the most commonly performed bariatric procedure is the proximal Roux-en-y gastric Bypass surgery. Since marginal ulceration is a known complication after this Operation, a Proton pump Inhibitor (PPI) prophylaxis is prescribed postoperatively. Bariatric surgery may have an impact on the absorption and consequently on the efficacy of drugs. There are only very little data on the pharmacokinetics of PPIs following PRYGB.

The aim of this study is to analyze the serum concentration of dexlansoprazole preoperative and after PRYGB surgery in patients taking PPI prophylaxis and to examine the incidence of marginal ulcers postoperatively in the same population.

Full description

This prospective, monocentric study includes 30 patients undergoing a proximal Roux-en-Y gastric Bypass surgery and receiving 6 months of postoperative PPI prophylaxis with Dexilant (dexlansoprazole). The aim is to examine if the LPRYGB has an impact on the absorption of dexlansoprazole. Peripheral blood samples from the study participants are obtained at fixed time points after oral Administration of a capsule Dexilant preoperatively as well as 3 and 6 months after surgery. The incidence of marginal ulceration in the same patient population is assessed by upper endoscopy 6 and 12 months after surgery. The surgery, the PPI prophylaxis and the upper endoscopy 12 months post-surgery aren't for study purpose. Data collection is made by measuring serum drug concentration, patient questionnaires, pill count and upper endoscopy.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Informed consent for study and surgery as documented by signature
• Male and Female Patients over 18 years old eligible for bariatric surgery at the Department of General Surgery, Limmattal Hospital, according to criteria of the Swiss Study Group for Morbid Obesity (SMOB) and international Guidelines
• BMI ≥ 35
• Failure of conservative Treatment for 2 years
• Type of surgery: LPRYGB
• Helicobacter pylori negative
• Smoker (≥ 1 cigarette daily)
• Women in reproductive Age: negative pregnancy test

Exclusion criteria

• Contraindication for a bariatric surgery according to SMOB-criteria
• Contraindication for PPIs
• Pregnant or breastfeeding women
• Pre- or intraoperative decision for other type of surgery than LPRYGB
• Active malignancy
• Chronic liver disease Child-Pugh B or C
• Abuse of drugs or alcohol
• Suspect of non-compliance

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

Dexlansoprazole

Other group

Description:

The PPI Dexilant (active substance: dexlansoprazole) is administered to the study participants in a prophylactic Regimen for 6 months after the PRYGB-surgery. This drug is already approved by Swissmedic and on the markets in Switzerland. The dosage is 1 capsule 60 mg per os daily in the morning.

Treatment:

Diagnostic Test: dexlansoprazole serum concentration

Diagnostic Test: upper endoscopy